Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study

BACKGROUND: Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ying, Mu, Di, Liu, Ting, Zhang, Huan, Zhang, Jiali, Li, Shuzhan, Wang, Rui, Du, Weijiao, Hui, Zhenzhen, Zhang, Xinwei, Ren, Xiubao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812069/
https://www.ncbi.nlm.nih.gov/pubmed/33150733
http://dx.doi.org/10.1111/1759-7714.13731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812069/
https://www.ncbi.nlm.nih.gov/pubmed/33150733
http://dx.doi.org/10.1111/1759-7714.13731

Ejemplares similares